BSX Q3 2024 Earnings — Boston Scientific Corporation Revenue & Financial Results | Market Cap Arena

BSXBoston Scientific Corporation

$105B

Q3 2024 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$4.2B+19.3% YoY

Gross Profit

$2.6B62.9% margin

Operating Income

$674M16.0% margin

Net Income

$469M11.1% margin

EPS (Diluted)

$0.32

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

$1.0B

Free Cash Flow

$698M

Stock-Based Comp.

-$61M

Balance Sheet

Total Assets

$38.1B

Total Liabilities

$17.1B

Stockholders' Equity

$20.7B

Cash & Equivalents

$2.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.2B	$3.5B	+19.3%
Gross Profit	$2.6B	$2.2B	+22.2%
Operating Income	$674M	$558M	+20.8%
Net Income	$469M	$504M	-6.9%

Revenue Segments

Cardiovascular

$2.7B65%

MedSurg

$1.5B35%

Geographic Segments

UNITED STATES

$2.6B62%

Non-US

$1.6B38%